An analysis of current measles vaccination program in the eastern Chinese province of Zhejiang (which provides 1 dose of measles-rubella vaccine at 8 months of age and 1 dose of MMR at 18 months) estimated that, for every dollar spent on immunization, the health system saves $6.06 in treatment costing, including the costs of treating complications and long-term sequelae, such as hearing loss.
Full Citation:
Zeng Y, Luo M, Chen J et al.. 2019. An economic evaluation of the current measles vaccination program: a case study in Zhejiang Province, east China. Vaccine. 37(23).
Title of Article: An economic evaluation of the current measles vaccination program: a case study in Zhejiang Province, east China
Author(s): Zeng Y, Luo M, Chen J et al.
Publication Year: 2019
Publication Name: Vaccine
Publication Volume: 37(23)
Publication Source URL: https://pubmed.ncbi.nlm.nih.gov/31040084/
DOI (Digital Object Identifier): 10.1016/j.vaccine.2019.04.057
Topics: Economics & Return on Investment
Disease Vaccines: Measles
Immunization Terms: Return on investment
Countries: China
WHO Regions: Western Pacific